HER2+ Breast Cancer | Specialty

Neratinib Application Delayed for HER2+ Breast Cancer

March 30th 2016

Puma Biotechnology announced that it plans to delay the submission of a new drug application until mid-2016 for neratinib as an extended adjuvant treatment for patients with HER2-positive early breast cancer following a trastuzumab-based regimen.

ONT-380/T-DM1 Combo Shows Promise in HER2+ Breast Cancer With CNS Mets

March 28th 2016

Erika P. Hamilton, MD, discusses the significance of these trials and the impact ONT-380 may have on the treatment paradigm of HER2-positive breast cancer.

T-DM1 Now Standard for Heavily Pretreated HER2+ Breast Cancer

March 28th 2016

Hans Wildier, MD, provides an overview of the TH3RESA study and discusses the trial’s significance in the field of HER2-positive breast cancer.

Dr. Verma on Advancements in Treatment of HER2-Positive Breast Cancer

March 12th 2016

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses recent advancements in the field of HER2-positive breast cancer.

Neoadjuvant Treatment Now Mainstay in HER2+ Breast Cancer

February 29th 2016

Sunil Verma, MD, discusses emerging key agents in the neoadjuvant setting, advantages of treating prior to surgery, and questions that still remain regarding HER2-positive neoadjuvant therapy.

Key Studies Help Chart Course in HER2-Positive Breast Cancer

February 28th 2016

Among the bright spots in the treatment of patients with breast cancer are the successes achieved in the management of HER2-positive disease. And, therapeutic options are continuing to expand, owing to the advent of novel anti-HER2–targeted agents and multitargeted HER2 receptor blockade.

Advances on the Horizon for ER+/HER2+ Breast Cancer, But Questions Remain

February 26th 2016

Sunil Verma, MD, discusses advancing treatment in ER+/HER2+ breast cancer, specific therapies that should be considered for this subgroup, upcoming clinical trials, and the biggest challenges and questions that remain in this setting.

Blackwell on Recent Advances in HER2-Positive Breast Cancer

February 25th 2016

Kimberly L. Blackwell, MD, discusses recent studies examining emerging agents in HER2-positive breast cancer.

Dr. Erika P. Hamilton on ONT-380 for HER2+ Breast Cancer

February 25th 2016

Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator, Sarah Cannon Research Institute, discusses ONT-380, a novel HER2-specific inhibitor. Most oral HER2-inhibitors block not only HER2, but other proteins such as EGFR.

Neratinib Improves DFS in HER2-Positive Breast Cancer

February 12th 2016

Treatment with the tyrosine kinase inhibitor neratinib demonstrated a 2-year disease-free survival rate of 93.9% in patients with early-stage HER2-positive breast cancer, representing a 33% improvement compared with placebo.

ASCO Guideline Clarifies Biomarker Assay Use in Adjuvant Breast Cancer Care

February 8th 2016

ASCO released new evidence-based recommendations to ensure appropriate use of biomarker assay results in guiding decisions on adjuvant therapy for women with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status.

Prospects in the Management of Breast Cancer

February 2nd 2016

Immunotherapy in Breast Cancer

February 2nd 2016

Analyzing the Use of Eribulin in Metastatic Breast Cancer

February 2nd 2016

Neoadjuvant Treatment in Triple-Negative Breast Cancer

February 2nd 2016

Post-Adjuvant Breast Cancer Treatment

February 2nd 2016

Neoadjuvant Therapy for HER2+ Breast Cancer

February 2nd 2016

MARIANNE and BOLERO-1 Trial Results in Breast Cancer

February 2nd 2016

First-Line Treatment of HER2-Positive MBC

February 2nd 2016

Managing Mouth Sores in Patients with Breast Cancer

February 2nd 2016